前列腺癌主动监测的前瞻性验证：PRIAS研究 - Suppr

Suppr

超能文献

Prospective validation of active surveillance in prostate cancer: the PRIAS study.

作者信息

van den Bergh Roderick C N, Roemeling Stijn, Roobol Monique J, Roobol Wouter, Schröder Fritz H, Bangma Chris H

出版信息

Eur Urol. 2007 Dec;52(6):1560-3. doi: 10.1016/j.eururo.2007.05.011. Epub 2007 May 25.

DOI:10.1016/j.eururo.2007.05.011

PMID:17532115

Abstract

摘要

相似文献

Prospective validation of active surveillance in prostate cancer: the PRIAS study.

Eur Urol. 2007 Dec;52(6):1560-3. doi: 10.1016/j.eururo.2007.05.011. Epub 2007 May 25.

Prostate cancer screening: is it possible to explain diametrically opposed views?

N Z Med J. 2005 Feb 11;118(1209):U1289.

Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.

J Urol. 2010 Nov;184(5):2214-5; author reply 2215. doi: 10.1016/j.juro.2010.06.128. Epub 2010 Sep 22.

Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11.

Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.

Int J Urol. 2009 Sep;16(9):711-12.

Screening for prostate cancer with serum prostate-specific antigen : what should we recommend while waiting for randomized clinical trial results?

Cancer. 2008 Dec 1;113(11):3067-8. doi: 10.1002/cncr.23933.

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.

Urol Oncol. 2009 Nov-Dec;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Eur Urol. 2009 Jun;55(6):1331. doi: 10.1016/j.eururo.2009.02.030. Epub 2009 Mar 6.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6.

PSA testing and DRE, TRUS scanning with sector biopsy, improved histology, curative treatments, and active surveillance for prostate cancer: a success story for men's health.

N Z Med J. 2008 Dec 12;121(1287):57-68.

引用本文的文献

The evolving landscape: magnetic resonance imaging in active surveillance for prostate cancer management.

Front Urol. 2024 Apr 12;4:1329274. doi: 10.3389/fruro.2024.1329274. eCollection 2024.

Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.

BJU Int. 2025 Aug;136(2):245-253. doi: 10.1111/bju.16727. Epub 2025 Apr 14.

Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.

JAMA Netw Open. 2025 Jan 2;8(1):e2454366. doi: 10.1001/jamanetworkopen.2024.54366.

Development and Validation of a Deep Learning Model Based on MRI and Clinical Characteristics to Predict Risk of Prostate Cancer Progression.

Radiol Imaging Cancer. 2025 Jan;7(1):e240078. doi: 10.1148/rycan.240078.

Treatment of intermediate-risk prostate cancer with active surveillance in the routine care-Long-term outcomes of a prospective noninterventional study (HAROW).

Curr Urol. 2024 Jun;18(2):115-121. doi: 10.1097/CU9.0000000000000203. Epub 2024 Jun 21.

Transperineal Laser Ablation for Focal Therapy of Localized Prostate Cancer: 12-Month Follow-up Outcomes from a Single Prospective Cohort Study.

Cancers (Basel). 2024 Jul 23;16(15):2620. doi: 10.3390/cancers16152620.

Longitudinal evaluation of MRI findings, including quantitative apparent diffusion coefficient values, might be necessary to predict disease progression in patients with prostate cancer on active surveillance.

World J Urol. 2024 Mar 26;42(1):191. doi: 10.1007/s00345-024-04932-3.

Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors.

World J Mens Health. 2024 Jul;42(3):587-599. doi: 10.5534/wjmh.230107. Epub 2023 Sep 26.

Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI/transrectal ultrasonography fusion biopsy in confirmatory biopsy during active surveillance program.

Prostate Cancer Prostatic Dis. 2024 Mar;27(1):129-135. doi: 10.1038/s41391-023-00733-8. Epub 2023 Oct 12.

Changing nationwide trends away from overtreatment among patients undergoing radical prostatectomy over the past 25 years.

World J Urol. 2023 Jun;41(6):1497-1502. doi: 10.1007/s00345-023-04418-8. Epub 2023 May 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验